Inhibrx Stock Annual Yield

INBX Stock

USD 14.86 0.78 5.54%

Inhibrx fundamentals help investors to digest information that contributes to Inhibrx's financial success or failures. It also enables traders to predict the movement of Inhibrx Stock. The fundamental analysis module provides a way to measure Inhibrx's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inhibrx stock.

Total Current Liabilities Other Current Liab

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Inhibrx Company Annual Yield Analysis

Inhibrx's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.

Yield

Income from Security

Current Share Price

More About Annual Yield | All Equity Analysis

Inhibrx Annual Yield Driver Correlations

Understanding the fundamental principles of building solid financial models for Inhibrx is extremely important. It helps to project a fair market value of Inhibrx Stock properly, considering its historical fundamentals such as Annual Yield. Since Inhibrx's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inhibrx's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inhibrx's interrelated accounts and indicators.

	Net Tangible Assets	Retained Earnings	Accounts Payable	Total Current Assets	Property Plant Equipment	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Deferred Long Term Liab	Capital Stock	Common Stock	Long Term Debt Total	Capital Surpluse
Net Tangible Assets		-0.72	0.65	0.81	0.14	0.81	0.98	-0.71	-0.94	0.68	-0.02	0.5	0.84	-0.59	0.82	-0.78	-0.49	0.91	0.91	0.67	0.63
Retained Earnings	-0.72		-0.63	-0.97	-0.17	-0.97	-0.7	0.57	0.76	-0.97	0.26	-0.87	-0.94	0.75	-0.96	0.59	0.81	-0.83	-0.83	-0.97	-0.9
Accounts Payable	0.65	-0.63		0.69	0.68	0.71	0.76	-0.3	-0.85	0.56	-0.2	0.6	0.66	-0.72	0.68	-0.82	-0.3	0.71	0.71	0.5	0.52
Total Current Assets	0.81	-0.97	0.69		0.18	1.0	0.81	-0.62	-0.85	0.97	-0.36	0.86	0.99	-0.76	1.0	-0.71	-0.72	0.86	0.86	0.96	0.9
Property Plant Equipment	0.14	-0.17	0.68	0.18		0.21	0.28	0.46	-0.38	0.07	-0.12	0.21	0.1	-0.68	0.17	-0.63	0.06	0.11	0.11	-0.03	0.0
Total Assets	0.81	-0.97	0.71	1.0	0.21		0.81	-0.6	-0.86	0.97	-0.36	0.87	0.99	-0.78	1.0	-0.73	-0.72	0.85	0.85	0.95	0.89
Total Stockholder Equity	0.98	-0.7	0.76	0.81	0.28	0.81		-0.65	-0.98	0.67	-0.08	0.53	0.83	-0.65	0.82	-0.87	-0.41	0.9	0.9	0.63	0.62
Current Deferred Revenue	-0.71	0.57	-0.3	-0.62	0.46	-0.6	-0.65		0.59	-0.59	-0.08	-0.39	-0.67	0.04	-0.64	0.27	0.47	-0.76	-0.76	-0.64	-0.61
Net Debt	-0.94	0.76	-0.85	-0.85	-0.38	-0.86	-0.98	0.59		-0.72	0.16	-0.62	-0.87	0.73	-0.86	0.89	0.45	-0.91	-0.91	-0.68	-0.67
Long Term Debt	0.68	-0.97	0.56	0.97	0.07	0.97	0.67	-0.59	-0.72		-0.43	0.9	0.96	-0.71	0.97	-0.59	-0.75	0.76	0.76	0.99	0.93
Net Receivables	-0.02	0.26	-0.2	-0.36	-0.12	-0.36	-0.08	-0.08	0.16	-0.43		-0.42	-0.38	0.33	-0.38	0.31	0.15	0.08	0.08	-0.38	-0.28
Total Liab	0.5	-0.87	0.6	0.86	0.21	0.87	0.53	-0.39	-0.62	0.9	-0.42		0.83	-0.77	0.86	-0.51	-0.49	0.69	0.69	0.87	0.95
Net Invested Capital	0.84	-0.94	0.66	0.99	0.1	0.99	0.83	-0.67	-0.87	0.96	-0.38	0.83		-0.72	0.99	-0.7	-0.69	0.87	0.87	0.95	0.89
Short Long Term Debt	-0.59	0.75	-0.72	-0.76	-0.68	-0.78	-0.65	0.04	0.73	-0.71	0.33	-0.77	-0.72		-0.76	0.81	0.39	-0.6	-0.6	-0.63	-0.67
Net Working Capital	0.82	-0.96	0.68	1.0	0.17	1.0	0.82	-0.64	-0.86	0.97	-0.38	0.86	0.99	-0.76		-0.73	-0.69	0.86	0.86	0.95	0.9
Short Term Debt	-0.78	0.59	-0.82	-0.71	-0.63	-0.73	-0.87	0.27	0.89	-0.59	0.31	-0.51	-0.7	0.81	-0.73		0.25	-0.65	-0.65	-0.5	-0.47
Deferred Long Term Liab	-0.49	0.81	-0.3	-0.72	0.06	-0.72	-0.41	0.47	0.45	-0.75	0.15	-0.49	-0.69	0.39	-0.69	0.25		-0.54	-0.54	-0.79	-0.56
Capital Stock	0.91	-0.83	0.71	0.86	0.11	0.85	0.9	-0.76	-0.91	0.76	0.08	0.69	0.87	-0.6	0.86	-0.65	-0.54		1.0	0.76	0.81
Common Stock	0.91	-0.83	0.71	0.86	0.11	0.85	0.9	-0.76	-0.91	0.76	0.08	0.69	0.87	-0.6	0.86	-0.65	-0.54	1.0		0.76	0.81
Long Term Debt Total	0.67	-0.97	0.5	0.96	-0.03	0.95	0.63	-0.64	-0.68	0.99	-0.38	0.87	0.95	-0.63	0.95	-0.5	-0.79	0.76	0.76		0.93
Capital Surpluse	0.63	-0.9	0.52	0.9	0.0	0.89	0.62	-0.61	-0.67	0.93	-0.28	0.95	0.89	-0.67	0.9	-0.47	-0.56	0.81	0.81	0.93

Click cells to compare fundamentals

Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.

Competition

Predict Inhibrx

Inhibrx Dividend Yield

Dividend Yield

0.002089

At this time, Inhibrx's Dividend Yield is fairly stable compared to the past year.

In accordance with the recently published financial statements, Inhibrx has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Price Transformation Now

Price Transformation

Use Price Transformation models to analyze the depth of different equity instruments across global markets

All Next

Launch Module

Inhibrx ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inhibrx's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inhibrx's managers, analysts, and investors.

Environmental

Governance

Social

Inhibrx Fundamentals

	Return On Equity	-20.31
	Return On Asset	-0.57
	Profit Margin	1,020 %
	Current Valuation	9.32 M
	Shares Outstanding	14.48 M
	Shares Owned By Insiders	23.54 %
	Shares Owned By Institutions	67.49 %
	Number Of Shares Shorted	976.67 K
	Price To Book	1.14 X
	Price To Sales	120.82 X
	Revenue	1.8 M
	Gross Profit	(107.99 M)
	EBITDA	(206.69 M)
	Net Income	(241.36 M)
	Cash And Equivalents	176.38 M
	Cash Per Share	4.52 X
	Total Debt	210.14 M
	Debt To Equity	4.22 %
	Current Ratio	7.51 X
	Book Value Per Share	15.15 X
	Cash Flow From Operations	(193.31 M)
	Short Ratio	14.06 X
	Earnings Per Share	119.39 X
	Target Price	15.0
	Number Of Employees	166
	Beta	2.88
	Market Capitalization	203.82 M
	Total Asset	307.89 M
	Retained Earnings	(613.73 M)
	Working Capital	239.05 M
	Net Asset	307.89 M

About Inhibrx Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Inhibrx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibrx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibrx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC